Anti-Cd30 Bispecific Antibody-Armed Anti-Cd3-Activated Autologous T-Cells
CD30+ Immunoblastic Large T-Cell Cutaneous Lymphoma
Medical College of WisconsinCell therapyPhase 1Active
CC
43/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 28/ 100
- Competitive Position
- 95/ 100
Competitive context
1 Active assets in the CD30+ Immunoblastic Large T-Cell Cutaneous Lymphoma cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
Gm-Csf Medical College of Wisconsin | Phase 1 | CC |
Genetically Modified T Cells # 1138 | Phase 1 | CC |
Same molecule, other indications
Anti-Cd30 Bispecific Antibody-Armed Anti-Cd3-Activated Autologous T-Cells is also rated in:
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →